Cough mixture abuse as a novel cause of folate deficiency: a prospective, community-based, controlled study Cough mixture abuse has been reported to cause severe folate deficiency and neurological defects. We carried out a prospective case-controlled survey to confirm this association and define the incidence and severity of the problem. A total of 57 cough mixture abusers and 47 other substance abusers (controls) were studied. When compared with controls, cough mixture abusers had a high incidence of low folate levels that could only be detected by screening. Haematologica 2007; 92: 562-563 Cough mixture abuse accounts for 3% of all registered substances abusers in Hong Kong (HK).
/L, p=0.015) but comparable hemoglobin concentration (14.3 vs 13.7 g/dL, p=0.07) and mean cell volume (90.0 vs 90.2 fL, p=0.42). The incidence of folate and vitamin B12 deficiencies among cough mixture abusers was 39% (control 6.3%, p<0.001, RR=6.0) and 21% (control 0%), respectively. There was a strong correlation between folate and vitamin B12 levels (p=0.004, R=0.28) and eight patients had concomitant deficiencies in both. The folate-deficient cases consumed a greater volume of cough mixture (481 mL vs. 188 mL, p=0.006).
Although codeine and dextromethophan are both opiates, folate (p=0.004) and vitamin B12 (p=0.004) levels were lower, and platelet counts higher (p=0.003) among cough mixture abusers than among heroin abusers. These values showed no difference between codeine and dextromemorphan abusers. An analysis of metabolites showed no statistically significant differences between cough mixture abusers and controls with regards to HC (21.1 vs 22.5 umol/L, p=0.18) and MMA levels (0.41 vs 0.27 µmol/L, p=0.46). However, when patients with low Fo and B12 were compared against the rest of cohort, folate-deficient patients had higher HC levels. On the other hand, MMA levels were not increased in folate or vitamin B12-deficient cases (Table 1) .
Macrocytosis (MCV>96 fL) was a poor marker of folate deficiency. Among 18 macrocytic patients (range 96.2-109.8 fL), only 9/18 were cough mixture abusers, and 7/18 had low folate levels. The cough mixture abusers reported psychosis (n=25), numbness (n=23), weakness (n=11), dizziness (n=6) and dental carries (n=49). Patients reporting numbness consumed more cough mixture (470 mL vs. 202 m, p=0.004) and had lower vitamin B12 level (223 vs. 228 pmol/L, p=0.039), while those with psychosis had lower vitamin B12 levels (227 vs. 285 pmol/L, p=0.031), higher HC (24.1 vs. 18.4 µmol/L, p=0.03) and higher consumption of cough mixture (419 mL vs. 223 mL, p=0.04). There was no symptomatic association with folate findings.
Our prospective data showed that cough mixture abuse is associated with low folate levels. This is unrelated to concomitant drug use or the type of cough suppressant (dextromethophan or codeine) abused, and may be dosedependent. The low folate levels were also unrelated to sugar consumption (absent in codeine pills).
7 Many patients also had low vitamin B12 levels, usually accompanied by low folate levels. Metabolite assays in our published hospital-based study had shown that this is sec- ondary to severe folate deficiency. 4 Similarly, in this community-based cohort, patients with low vitamin B12 levels had significantly raised levels of HC (characteristic of folate pathway blockade) but not significantly raised MMA. Finally, we found a novel but unexplained thrombocytosis in cough mixture abusers.
Due to voluntary participation, our study cases may not be representative of all cough mixture abusers. 8 We also failed to identify dietary, genetic and life-style risks for folate deficiency present in 6% of the controls. 9 However, our prospective, community-based study showed that clinical symptoms and hematologic parameters are a poor guide to folate deficiency in at-risk populations. Hence, prospective screening and vitamin supplementation may be needed. 
